Largest Multi-Country Real-World Study Shows Broncho-Vaxom® Reduces Respiratory Tract Infections

OM Pharma is set to unveil preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. This is the largest multi-country real-world evidence study to date, evaluating the impact of Broncho-Vaxom® (OM-85) in over 15,790 patients across China, Italy, and Belgium with recurrent respiratory tract infections (RTIs). The study met its primary endpoint, showing a 28-38% reduction in RTI rates at 12 months and a 29-41% reduction at 24 months, regardless of previous infection frequency or age.